Clinical trials: cyclosporine
Cicatricial Alopecia, Lichen Planopilaris
a Retrospective Study on the Systemic Treatment of LPP and FFA
This retrospective study aims to assess the effectiveness of systemic treatments for lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) in patients treated at the Erasmus MC University Medical Center.
- Conditions
- Cicatricial Alopecia, Lichen Planopilaris, Lichen Plano-Pilaris, Frontal Fibrosing Alopecia
- Trial name
- NCT06512766
- Testing
- Hydroxychloroquine, Methotrexate, Cyclosporine A
- Where
- Netherlands
- Volunteers
- 315 people
- Sponsor
- Erasmus Medical Center
aGVHD, cGVHD
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling…
- Trial name
- NCT05214066
- Testing
- Rabbit ATG
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Glaucoma
Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?
The purpose of this study is to determine whether reducing inflammation of the surface of the eye with topical Restasis after glaucoma surgery will improve surgical outcomes and increase patient comfort.
- Trial name
- NCT00405431
- Testing
- Restasis, Endura (artificial tears)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Wills Eye
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Epstein-Barr Virus Infections
Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft
Epstein Barr virus infects over 90% of human population and persists during lifetime. After infecting B lymphocytes, EBV remains latent in memory B cells.
- Trial name
- REPLY (NCT04989491)
- Testing
- Rituximab, control group
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
End Stage Renal Disease
The Vienna Prograf and Endothelial Progenitor Cell Study
The aim of the study is to determine if the conversion from the immunosuppressive agent cyclosporine to tacrolimus contributes to an improvement of the cardiovascular risk factors, better kidney function and immune system.
- Trial name
- NCT00182559
- Testing
- Ciclosporin, Tacrolimus
- Where
- Austria
- Volunteers
- 148 people
- Sponsor
- Medical University of Vienna
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard…
- Trial name
- NCT00928018
- Testing
- Sirolimus, Methotrexate, Tacrolimus
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Dana-Farber Cancer Institute
Connective Tissue Diseases, Thrombocytopenia
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.
- Trial name
- NCT05998759
- Testing
- Telitacicept
- Where
- 23 sites in China
- Volunteers
- 296 people
- Sponsor
- Beijing Hospital
Hematologic Malignancy, Myeloid Malignancy
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
- Trial name
- NCT05579769
- Testing
- Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- St. Jude Children's Research Hospital
Metastatic Breast Cancer
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer
The purpose of this research study is to evaluate the safety of therapy with nab-paclitaxel and CsA and if the addition of Cyclosporine A (CsA) to nab-paclitaxel helps stop cancer cells as well as or better than nab-paclitaxel…
- Trial name
- NCT00983424
- Testing
- Cyclosporins, nab-paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003661
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Dry Eye Syndromes
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.
- Trial name
- NCT00502073
- Testing
- cyclosporine
- Where
- United States
- Sponsor
- Sirion Therapeutics, Inc.
Immunosuppression
Microsampling Assays for Immunosuppressive Drugs in Children
Immunosuppressive therapy is used to treat and manage solid organ and bone marrow/stem cell transplants in children. However, it can be harmful if too little or too much is given.
- Trial name
- MAIDEN (NCT04989686)
- Testing
- Microsampling
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Children's Hospital of Philadelphia
Venous Thromboembolism, Pharmacokinetics
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers.
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Trial name
- ACT (NCT03083782)
- Testing
- Apixaban alone, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Hematologic Malignancies, Disorder Related to Transplantation
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Conditions
- Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy
- Trial name
- NCT01328496
- Testing
- Preparative Regimen
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
Transfusion-dependent Non-severe Aplastic Anemia
Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA
This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine alone in the treatment of TD-NSAA.
- Trial name
- NCT07522996
- Testing
- Enarodustat, Cyclosporin (CSA)
- Sponsor
- Peking Union Medical College Hospital
Colitis, Ulcerative
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on…
- Trial name
- NCT03844932
- Testing
- ST-0529
- Where
- 89 sites in United States, Belarus and 15 more
- Volunteers
- 235 people
- Sponsor
- Sublimity Therapeutics Holdco Limited
Anemia, Leukemia, T-Cell
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine
T Cell Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders are a heterogeneous group of uncommon diseases which may involve a polyclonal or a monoclonal T cell population, which bear characteristic surface markers…
- Conditions
- Anemia, Leukemia, T-Cell, Lymphocytosis, Neutropenia
- Trial name
- NCT00001533
- Testing
- cyclosporine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Hepatitis C, Organ Transplantation
Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen
Liver transplant subjects will be given Mycophenolate (MMF) and Tacrolimus in order to help prevent post-transplant rejection.
- Conditions
- Chronic Hepatitis C, Organ Transplantation, Immunosuppression
- Trial name
- NCT00286871
- Testing
- Neoral, Tacrolimus
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Severe Aplastic Anemia
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Background: Severe aplastic anemia is a rare and serious blood disorder. It happens when the immune system starts to attack the bone marrow cells.
- Trial name
- NCT01623167
- Testing
- Cohort 1: hATG, CsA, EPAG Day 14 to Month 6, Cohort 2: hATG, CsA, EPAG Day 14 to Month 3, Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.